You are here

  • Home
  • Archive
  • Volume 88, Issue 5
  • A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

Article metrics

Article menu
Download PDFPDF
Poster Abstracts
Abstracts
63
A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

 

Online download statistics by month:

Online download statistics by month: May 2017 to March 2024

AbstractFullPdf
May 2017139020
Jun 2017138019
Jul 2017144010
Aug 2017200017
Sep 2017320017
Oct 2017272020
Nov 2017453021
Dec 201731603
Jan 2018448021
Feb 2018496029
Mar 201846009
Apr 2018354022
May 2018418014
Jun 2018436010
Jul 2018372014
Aug 2018444014
Sep 201826707
Oct 2018380017
Nov 2018378010
Dec 2018656010
Jan 2019412014
Feb 201910604
Mar 201915205
Apr 201915004
May 20199205
Jun 20197605
Jul 20198602
Aug 20195801
Sep 201910008
Oct 20198001
Nov 20196201
Dec 20195602
Jan 20208002
Feb 20207401
Mar 20204401
Apr 20204001
May 20206800
Jun 20204002
Jul 20203402
Aug 20205000
Sep 202011401
Oct 20205401
Nov 20204801
Dec 20202600
Jan 20214601
Feb 20214200
Mar 202112203
Apr 20215202
May 20211800
Jun 2021002
Oct 202115400
Nov 20215200
Dec 20214800
Jan 20225201
Feb 20226601
Mar 202210405
Apr 20228800
May 202211400
Jun 20229203
Jul 20224502
Aug 20225802
Sep 20225001
Oct 202219403
Nov 20228200
Dec 20224001
Jan 20233000
Feb 20238800
Mar 20231800
Apr 20232200
May 20233000
Jun 20234800
Jul 20233202
Aug 20231600
Sep 20233200
Oct 20231400
Nov 20234801
Dec 2023600
Jan 2024800
Feb 20241700
Mar 20241000
Total111310398